Correlation analysis of the Her-2 gene amplification and clinicopathologic meaning and the prognosis in gastric cancer

doi:10.3877/cma.j.issn.1674-0793.2011.06.006

Abstract

Abstract:

Objective

To detect the amplification proportion of the Her-2 gene, explore the association of the Her-2 gene amplification with the clinical and pathological meaning and the prognosis in gastric cancer.

Methods

Sixty-two cases of gastric cancer were detected by fluorescence in situ hybridization(FISH), analyzed the correlation of the Her-2 gene amplification and clinicopathologic parameters and the prognosis in gastric cancer.

Results

The amplification of Her-2 gene existed in 10 cases (16.1%) while 52 cases had no Her-2 gene amplification (83.9%). Her-2 gene amplification was associated with histologic T grade, regional lymph node and stage, and distant metastasis (P < 0.05). No association was found with sex,age,site of tumor, vessel infiltrating and CEA > 5 μg/L. By Kaplan-Meier analysis, the survival time was shorter in the patients with positive Her-2 amplification than in those with negative Her-2 amplification.

Conclusion

The amplification of Her-2 gene is significantly related with the clinical and pathological characters and overall 5-year survival rate in gastric cancer.

Key words: Gastric cancer, Her-2 gene, Amplification, Clinicopathological character, Prognosis

Long-bin XIAO, Shi-bin YANG, Wen-hui WU, Shuo LONG, Ming-zhe LI. Correlation analysis of the Her-2 gene amplification and clinicopathologic meaning and the prognosis in gastric cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2011, 05(06): 480-484.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2011.06.006

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2011/V05/I06/480

Figures/Tables 4

References 15

1	Simona C, Elena G, Virna C, et al. Research activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer, 2010,121(9):2-13.
2	Sebastian S, Settleman J, Reshkin SJ, et al. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta, 2006,1766(1):120-139.
3	Ignatiadis M, Desmedt C, Sotiriou C, et al. Her-2 as a target for-breast cancer therapy. Clin Cancer Res, 2009,15(6):1848-1852.
4	Lordick F, Bang YJ, Kang YK, et al. HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer. Eur J Cancer, 2007,5(4):271.
5	曾瑄, 赵大春, 周炜洵, 等. 荧光原位杂交检测乳腺癌Her-2基因状态. 中华病理学杂志, 2005,34(11):701-705.
6	秦叔逵, 龚新雷. 晚期胃癌的化疗的现状和新进展. 临床肿瘤学杂志, 2006,11(9):641-652.
7	Penault-Llorca F, Bilous M, Dowsett M, et al. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol, 2009,132(4):539-540.
8	董海新, 张仁亚, 刘启龙, 等. 荧光原位杂交技术检测乳腺癌Her-2/neu基因与免疫组化法检测C-erbB2蛋白的相关性研究. 分子诊断与治疗杂志, 2009,1(2):77-82.
9	唐录英, 何丹, 周静, 等. 荧光原位杂交和免疫组织化学方法检测乳腺癌组织中人类表皮生长因子受体2基因状态差异及其特征分析[J/CD]. 中华乳腺病杂志:电子版, 2010, 4(1):70-77.
10	宋宝, 郑刚, 谢丽, 等. 乳腺癌组织与转移淋巴结Her-2基因表达及检测方法的比较. 肿瘤防治研究, 2011,38(1):78-82.
11	Kong YC, Jacob JB, Flynn JC, et al. Autoimmune thyroiditis as an indicator of autoimmune sequelae during cancer mmuno-therapy. Autoimmun Rev, 2009,9(1):28-33.
12	Yan SY, Hu Y, Fan JG, et al. Clinicopathologic significance of Her-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol, 2011,17(11):1501-1506.
13	Yan B, Yau EX, Bte Omar SS, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol, 2010,63(9):839-842.
14	Sato T, Abe K, Kurose A, et al. Amplification of the c-erbB-2 gene detected by FISH in gastric cancers. Pathology International, 1997,47(2-3):179-182.
15	Marx AH, Tharun L, Muth J, et al. Her-2 amplification is highly homogenous in gastric cancer. Hum Pathol, 2009,40(6):769-777.

组别		例数	Her-2基因扩增	χ²值	P值
性别		?	?	?	?
?	男	42	6(14.3)	0.327	0.567
?	女	20	4(20.0)	?	?
年龄(岁)		?	?	?	?
?	< 60	32	3(9.4)	2.230	0.135
?	≥60	30	7(23.3)	?	?
病变部位		?	?	?	?
?	胃窦	32	6(18.8)	?	?
?	胃体	9	2(22.2)	1.087	0.581
?	贲门	21	2(9.5)	?	?
分化程度		?	?	?	?
?	高	16	0(0.0)	?	?
?	中	17	2(11.8)	6.130	0.047^*
?	低	29	8(27.6)	?	?
CEA增高		?	?	?	?
?	> 5 μg/L	27	4(14.8)	0.061	0.805
?	正常	35	6(17.1)	?	?
血管受侵		?	?	?	?
?	侵犯	17	3(17.6)	0.040	0.842
?	未侵犯	45	7(15.6)	?	?
远处转移		?	?	?	?
?	无	54	6(11.1)	7.790	0.005^*
?	有	8	4(50.0)	?	?
T分期		?	?	?	?
?	T1	5	0(0.0)	?	?
?	T2	10	0(0.0)	9.135	0.028^*
?	T3	18	1(5.6)	?	?
?	T4	29	9(31.0)	?	?
N分期		?	?	?	?
?	N0	16	0(0.0)	4.147	0.042^*
?	≥N1	46	10(21.7)	?	?

组别		例数	Her-2基因扩增	χ²值	P值
性别		?	?	?	?
?	男	42	6(14.3)	0.327	0.567
?	女	20	4(20.0)	?	?
年龄(岁)		?	?	?	?
?	< 60	32	3(9.4)	2.230	0.135
?	≥60	30	7(23.3)	?	?
病变部位		?	?	?	?
?	胃窦	32	6(18.8)	?	?
?	胃体	9	2(22.2)	1.087	0.581
?	贲门	21	2(9.5)	?	?
分化程度		?	?	?	?
?	高	16	0(0.0)	?	?
?	中	17	2(11.8)	6.130	0.047^*
?	低	29	8(27.6)	?	?
CEA增高		?	?	?	?
?	> 5 μg/L	27	4(14.8)	0.061	0.805
?	正常	35	6(17.1)	?	?
血管受侵		?	?	?	?
?	侵犯	17	3(17.6)	0.040	0.842
?	未侵犯	45	7(15.6)	?	?
远处转移		?	?	?	?
?	无	54	6(11.1)	7.790	0.005^*
?	有	8	4(50.0)	?	?
T分期		?	?	?	?
?	T1	5	0(0.0)	?	?
?	T2	10	0(0.0)	9.135	0.028^*
?	T3	18	1(5.6)	?	?
?	T4	29	9(31.0)	?	?
N分期		?	?	?	?
?	N0	16	0(0.0)	4.147	0.042^*
?	≥N1	46	10(21.7)	?	?

组别	5年生存		3年生存		1年生存		合计
组别	存活	死亡	存活	死亡	存活	死亡	合计
Her-2(+)	1	9	4	6	8	2	10
Her-2(-)	23^*	29	36	16	45	7	52
χ²值	4.142		3.130		0.289		?
P值	0.042		0.077		0.591		?

组别	5年生存		3年生存		1年生存		合计
组别	存活	死亡	存活	死亡	存活	死亡	合计
Her-2(+)	1	9	4	6	8	2	10
Her-2(-)	23^*	29	36	16	45	7	52
χ²值	4.142		3.130		0.289		?
P值	0.042		0.077		0.591		?

[1]	Xiaoyu Zhang, Yulai Yin, Yinxu Zhang. Efficacy and prognostic analysis of apatinib combined with neoadjuvant chemotherapy in triple negative breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 346-352.
[2]	Jie Xu, Yajun Li, Junwei Han. Comparison of the efficacy of radical laparoscopic total gastrectomy in the treatment of overweight gastric cancer with two approaches [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 19-22.
[3]	Jiehong Gao, Pingping Li, Jing Qi, Yinhai Dai. Study on the relationship between the expression of ETFA gene and clinicopathological parameters and prognosis in breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 64-67.
[4]	Daiqin Li, Peijie Liu. Value of dynamic enhanced magnetic resonance imaging in evaluating the efficacy and prognosis of middle and advanced low rectal cancer after concurrent chemoradiotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 100-103.
[5]	Xiangyu Qu, Yigang Zhang, Haoling Li, Tian Qiu, Yi Tan. Diagnostic and prognostic role of USP24 and its co-expression of tumor metabolic genes in hepatocellular carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 659-662.
[6]	Wen Gu, Shouxin Ling, Haili Tang, Xuemei Gan. Comparison of two different surgical approaches for open radical surgery in patients with papillary thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 687-690.
[7]	Chengwang Fu, Dagang Yang, Rong Wang, Futang Li. Research progress of nutritional and inflammatory markers in resectable pancreatic cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 704-708.
[8]	Mengjie Liang, Huanhuan Zhu, Xingzhou Wang, Hang Jiang, Shichao Ai, Feng Sun, Peng Song, Meng Wang, Song Liu, Xuefeng Xia, Junfeng Du, Shuang Fu, Xiaofeng Lu, Xiaofei Shen, Wenxian Guan. Analysis of prognosis and postoperative complications of gastric cancer patients undergoing conversion therapy with combined immunotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 619-623.
[9]	Zhizhao Zhang, Rui Wang, Pingping Gao, Chengfang Wang, Cheng Wang, Xiaowei Qi. Relationship between DNMT3B and prognosis of breast cancer and its biological mechanism [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 624-629.
[10]	Wei Li, Zijian Song, Yancheng Lai, Rui Zhou, Han Wu, Longxin Deng, Rui Chen. The current state and prospects of artificial intelligence applied to prognosis prediction in prostate cancer patients [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 541-546.
[11]	Zun Chen, Ping Wang, Hua Jin, Meiling Zhou, Qingqing Li, Yonggang Huang. Application of sarcopenia in predicting incisional hernia after colorectal cancer surgery [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2024, 18(06): 639-644.
[12]	Jiagang Han, Zhenjun Wang. The treatment strategies for obstructive left-sided colon cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 450-458.
[13]	Yu Liu, Shaobin Duan, Zhixiang Ding, Zhitao Shi. Expression of miR-34a-5p in colon cancer patients and its correlation with clinical characteristics and prognosis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 485-490.
[14]	Qianqian Chen, Chen Yuan, Ji Liu, Tingting Yin. Effects of multi-slice spiral CT parameters，carcinoembryonic antigen，mismatch repair gene，and pathological indicators on prognosis of colorectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 507-511.
[15]	Mingfen Zeng, Yan Wang. Study on the correlation between CT and color Doppler ultrasound diagnostic parameters and the condition and prognosis of patients with acute pancreatitis complicated with fatty liver [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 531-535.

Please choose a citation manager

Content to export